DK1773314T3 - Anvendelse af l-carnitin til behandling af kardiovaskulære sygdomme - Google Patents

Anvendelse af l-carnitin til behandling af kardiovaskulære sygdomme

Info

Publication number
DK1773314T3
DK1773314T3 DK05755616.9T DK05755616T DK1773314T3 DK 1773314 T3 DK1773314 T3 DK 1773314T3 DK 05755616 T DK05755616 T DK 05755616T DK 1773314 T3 DK1773314 T3 DK 1773314T3
Authority
DK
Denmark
Prior art keywords
carnitine
infarction
grams
care
days
Prior art date
Application number
DK05755616.9T
Other languages
Danish (da)
English (en)
Inventor
Aleardo Koverech
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Application granted granted Critical
Publication of DK1773314T3 publication Critical patent/DK1773314T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004Monosaccharides having only carbon, hydrogen and oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK05755616.9T 2004-07-13 2005-06-21 Anvendelse af l-carnitin til behandling af kardiovaskulære sygdomme DK1773314T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT000346A ITRM20040346A1 (it) 2004-07-13 2004-07-13 Uso della l-carnitina per il trattamento di patologie cardiovascolari.
PCT/EP2005/006657 WO2006005415A2 (en) 2004-07-13 2005-06-21 Use of l-carnitine and glucose for the treatment of cardiovascular diseases

Publications (1)

Publication Number Publication Date
DK1773314T3 true DK1773314T3 (da) 2012-05-07

Family

ID=34971575

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05755616.9T DK1773314T3 (da) 2004-07-13 2005-06-21 Anvendelse af l-carnitin til behandling af kardiovaskulære sygdomme

Country Status (21)

Country Link
US (2) US7879908B2 (https=)
EP (1) EP1773314B1 (https=)
JP (1) JP5230195B2 (https=)
KR (1) KR101296479B1 (https=)
CN (2) CN101087602B (https=)
AT (1) ATE542529T1 (https=)
AU (1) AU2005262050B2 (https=)
BR (1) BRPI0513303A8 (https=)
CA (1) CA2569888C (https=)
CY (1) CY1112686T1 (https=)
DK (1) DK1773314T3 (https=)
ES (1) ES2380913T3 (https=)
HR (1) HRP20120178T1 (https=)
IT (1) ITRM20040346A1 (https=)
ME (1) ME01345B (https=)
MX (1) MXPA06014665A (https=)
PL (1) PL1773314T3 (https=)
PT (1) PT1773314E (https=)
RS (1) RS52253B (https=)
SI (1) SI1773314T1 (https=)
WO (1) WO2006005415A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR086543A1 (es) * 2011-05-25 2014-01-08 Bg Medicine Inc Inhibidores de galectina-3 y metodos de uso de los mismos, composicion farmaceutica

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1120033B (it) * 1979-10-05 1986-03-19 Sigma Tau Ind Farmaceuti Composizione farmaceutica comprendente-carnitina adatta per l'alimentazione parenterale
JPS6415220A (en) 1987-07-06 1989-01-19 Mitsubishi Electric Corp Tension control device for utilizing maximum torque and maximum electric current of winding motor
JPH06102624B2 (ja) * 1990-08-10 1994-12-14 アース製薬株式会社 非心臓由来の不整脈防止薬
IT1261695B (it) 1993-06-02 1996-05-29 Sigma Tau Ind Farmaceuti Impiego di l-carnitina e alcanoil l-carnitine nella conservazione del sangue per trasfusioni e soluzioni stabilizzatrici che le contengono.
US5998386A (en) * 1997-09-19 1999-12-07 Feldman; Arthur M. Pharmaceutical compositions and method of using same for the treatment of failing myocardial tissue
AU1295700A (en) * 1998-11-26 2000-06-13 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of fumarate salt of l-carnitine or its alkanoyl derivatives in ischaemia
ATE336243T1 (de) * 1999-10-11 2006-09-15 Sigma Tau Ind Farmaceuti Verwendung von l-carnitin und seinen alkanoyl- derivaten als osmotisches mittel in lösungen für medizinische verwendung
WO2003082800A1 (en) * 2002-04-01 2003-10-09 The University Of Alberta Compounds that stimulate glucose utilization and methods of use
ITRM20030178A1 (it) * 2003-04-17 2004-10-18 Sigma Tau Ind Farmaceuti Uso della l-carnitina per il trattamento di patologie cardiovascolari.

Also Published As

Publication number Publication date
PT1773314E (pt) 2012-03-29
JP5230195B2 (ja) 2013-07-10
EP1773314A2 (en) 2007-04-18
BRPI0513303A8 (pt) 2017-12-26
RS52253B (sr) 2012-10-31
HRP20120178T1 (hr) 2012-05-31
AU2005262050A1 (en) 2006-01-19
PL1773314T3 (pl) 2012-06-29
ES2380913T3 (es) 2012-05-21
US20070207970A1 (en) 2007-09-06
US7879908B2 (en) 2011-02-01
CY1112686T1 (el) 2016-02-10
HK1113542A1 (en) 2008-10-10
CN101087602A (zh) 2007-12-12
ATE542529T1 (de) 2012-02-15
ME01345B (me) 2012-10-31
JP2008517872A (ja) 2008-05-29
WO2006005415A3 (en) 2006-05-26
US20110086917A1 (en) 2011-04-14
KR20070039541A (ko) 2007-04-12
WO2006005415A2 (en) 2006-01-19
HK1166003A1 (zh) 2012-10-19
AU2005262050B2 (en) 2011-02-24
SI1773314T1 (sl) 2012-04-30
CN101087602B (zh) 2011-09-14
KR101296479B1 (ko) 2013-08-13
CN102349923B (zh) 2016-04-27
BRPI0513303A (pt) 2008-05-06
ITRM20040346A1 (it) 2004-10-13
CA2569888C (en) 2013-08-13
CN102349923A (zh) 2012-02-15
CA2569888A1 (en) 2006-01-19
EP1773314B1 (en) 2012-01-25
MXPA06014665A (es) 2007-03-12
US8394854B2 (en) 2013-03-12

Similar Documents

Publication Publication Date Title
ES2577930T3 (es) Derivados de triazina para retrasar el inicio de la diabetes tipo 1
FI3628319T3 (fi) Hepaattisen enkefalopatian hoito rifaksimiinilla
AR040682A1 (es) Forma de dosificacion una vez al dia de pramipexol
ES2530719T3 (es) Formulaciones de oxicodona para ser administradas una vez al día
RU2015103107A (ru) Комбинированная композиция
AR045289A1 (es) Forma de dosificacion oral de liberacion controlada que comprende 4-(2-di-n-propilaminoetil) - 2(3h)-indolona (ropi-nirol) y uso de dicha forma de dosificacion para la elaboracion de un medicamento
EA200971073A1 (ru) Применение ранолазина при повышенном уровне натрийуретического пептида мозгового типа
AR036312A1 (es) Composicion farmaceutica
ECSP077843A (es) Tratamiento o prevención del prurito
KR20120089623A (ko) 정맥내 투여용 이부프로펜을 이용한 환자의 치료
ES2247060T3 (es) Producto que comprende un inhibidor de la transduccion de las señales de las proteinas g heterotrimericas en asociacion con un agente antihipertensor para una utilizacion terapeutica en el tratamiento de la hipertension arterial.
CY1112686T1 (el) Χρηση l-καρνιτινης για τη θεραπεια καρδιαγγειακων νοσηματων
JPS59116216A (ja) アルカノイルl−カルニチンを有効成分とするミオパシ−または筋ジストロフイ−治療剤
CA2593171A1 (en) Pharmaceutical composition and method for neoangiogenesis/revascularization useful in treating ischemic heart diseases
CA2493208A1 (en) Use of cilobradine or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure
BRPI0415322A (pt) composição farmacêutica antiretroviral, processo para a preparação de uma composição farmacêutica antiretroviral, método para reduzir a carga de consumo de pìlulas para um paciente, método para aumentar a meia-vida in vivo de lamivudina e de zidovudina enquanto não afetando a meia-vida de nevirapina
RU2012107483A (ru) Отамиксабан для лечения инфаркта миокарда без подъема сегмента st у пациентов пожилого возраста и пациентов с нарушенной функцией почек
MXPA05007612A (es) Uso de l-carnitina para el tratamiento de enfermedades cardiovasculares.
PE20240241A1 (es) Una composicion farmaceutica que comprende acido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxilo
Haessler et al. 2009 pandemic H1N1-associated myocarditis in a previously healthy adult
NO20061515L (no) Anvendelse av okskarbazepin for behandling av diabetisk neurpatisk smerte og forbedring av sovn
JP2006045200A (ja) 間質性膀胱炎の治療薬
Prabhu et al. Digital gangrene due to dopamine infusion-a case report
McDaniel Antidepressant activity of linezolid
Placebo-Controlled Original Research Efficacy and Safety of Adjunctive Armodafinil